135 related articles for article (PubMed ID: 35217362)
1. A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell.
Zhi L; Yin M; Su X; Zhang Z; Lu H; Li M; Guo C; Niu Z; Zhang X; Zhu W
Biochem Biophys Res Commun; 2022 Apr; 600():94-100. PubMed ID: 35217362
[TBL] [Abstract][Full Text] [Related]
2. A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis.
Lu C; Guo C; Chen H; Zhang H; Zhi L; Lv T; Li M; Niu Z; Lu P; Zhu W
Mol Immunol; 2020 May; 122():200-206. PubMed ID: 32388482
[TBL] [Abstract][Full Text] [Related]
3. A novel bispecific chimeric PD1-DAP10/NKG2D receptor augments NK92-cell therapy efficacy for human gastric cancer SGC-7901 cell.
Li M; Zhi L; Yin M; Guo C; Zhang H; Lu C; Zhu W
Biochem Biophys Res Commun; 2020 Mar; 523(3):745-752. PubMed ID: 31952789
[TBL] [Abstract][Full Text] [Related]
4. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren HG; Nahi H; Wagner AK; Alici E
Cancer Immunol Immunother; 2023 May; 72(5):1153-1167. PubMed ID: 36355079
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
6. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells.
Guo C; Wang X; Zhang H; Zhi L; Lv T; Li M; Lu C; Zhu W
Mol Immunol; 2019 Oct; 114():108-113. PubMed ID: 31351411
[TBL] [Abstract][Full Text] [Related]
7. TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects.
Li S; Zhang C; Shen L; Teng X; Xiao Y; Yu B; Lu Z
Cancer Immunol Immunother; 2023 Mar; 72(3):769-774. PubMed ID: 35988132
[TBL] [Abstract][Full Text] [Related]
8. Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma.
Kintz H; Nylen E; Barber A
Cell Immunol; 2020 May; 351():104069. PubMed ID: 32106933
[TBL] [Abstract][Full Text] [Related]
9. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
10. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
11. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy.
Zhang J; Sun R; Wei H; Zhang J; Tian Z
Oncol Rep; 2004 May; 11(5):1097-106. PubMed ID: 15069553
[TBL] [Abstract][Full Text] [Related]
12. Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells.
Liu H; Yang B; Sun T; Lin L; Hu Y; Deng M; Yang J; Liu T; Li J; Sun S; Jiao S
Oncol Rep; 2015 Jan; 33(1):95-102. PubMed ID: 25333815
[TBL] [Abstract][Full Text] [Related]
13. The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models.
Zheng J; Huang J; Ma W; Yang W; Hu B
Cancer Manag Res; 2021; 13():6045-6053. PubMed ID: 34377023
[TBL] [Abstract][Full Text] [Related]
14. NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.
Park HR; Ahn YO; Kim TM; Kim S; Kim S; Lee YS; Kim M; Keam B; Kim DW; Heo DS
Cytotherapy; 2019 Jun; 21(6):603-611. PubMed ID: 31010733
[TBL] [Abstract][Full Text] [Related]
15. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.
Chang YH; Connolly J; Shimasaki N; Mimura K; Kono K; Campana D
Cancer Res; 2013 Mar; 73(6):1777-86. PubMed ID: 23302231
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway.
Althaus J; Nilius-Eliliwi V; Maghnouj A; Döring S; Schroers R; Hudecek M; Hahn SA; Mika T
Cancer Immunol Immunother; 2023 Aug; 72(8):2573-2583. PubMed ID: 37052701
[TBL] [Abstract][Full Text] [Related]
18. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.
Meng F; Zhang S; Xie J; Zhou Y; Wu Q; Lu B; Zhou S; Zhao X; Li Y
J Hematol Oncol; 2023 Jun; 16(1):62. PubMed ID: 37316891
[TBL] [Abstract][Full Text] [Related]
19. An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR.
Zhao H; Zhou Z; Li G; Liu G; Lin S; Chen W; Xiong S
Cytotechnology; 2021 Aug; 73(4):539-553. PubMed ID: 34349345
[TBL] [Abstract][Full Text] [Related]
20. T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity.
Sailer N; Fetzer I; Salvermoser M; Braun M; Brechtefeld D; Krendl C; Geiger C; Mutze K; Noessner E; Schendel DJ; Bürdek M; Wilde S; Sommermeyer D
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
